Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Tobam

Tobam lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 25.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,622 shares of the biotechnology company’s stock after selling 541 shares during the period. Tobam’s holdings in Ascendis Pharma A/S were worth $223,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Westfield Capital Management Co. LP raised its holdings in shares of Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after acquiring an additional 170,942 shares during the last quarter. Janus Henderson Group PLC raised its stake in Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after purchasing an additional 267,881 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after purchasing an additional 155,971 shares in the last quarter. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth $60,000. Finally, ARS Investment Partners LLC grew its holdings in shares of Ascendis Pharma A/S by 0.9% during the fourth quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock worth $36,549,000 after buying an additional 2,369 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ASND shares. JPMorgan Chase & Co. boosted their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Wedbush restated an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Oppenheimer lowered their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S has an average rating of “Moderate Buy” and an average target price of $191.57.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $120.87 on Friday. The company’s 50 day simple moving average is $132.60 and its 200-day simple moving average is $132.49. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The company has a market capitalization of $7.34 billion, a price-to-earnings ratio of -14.96 and a beta of 0.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.